trending Market Intelligence /marketintelligence/en/news-insights/trending/KE26c9B8nHzC80-gmgfQLA2 content esgSubNav
In This List

Activist investor opposes Humana, Kindred deal

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

Anticipate the Unknown Go Beyond Fundamentals to Uncover Early Signs of Private Company Credit Deterioration

Blog

Taking Loss Given Default Estimation to the Next Level: An Aspiration for All Creditors, Not Just Banks


Activist investor opposes Humana, Kindred deal

Activist investor Brigade Capital Management opposed the deal by Humana Inc. and two private equity firms to buy Kindred Healthcare Inc., calling the deal value "disappointing and grossly inadequate."

Humana, Welsh Carson Anderson & Stowe and TPG Capital Management LP recently agreed to buy Kindred for $4.1 billion, or $9 per share.

The investor, which holds a 5.8% stake in the medical-facility operator, plans to vote against the transaction.

In a letter, Brigade said the "deal price is not reflective of Kindred's intrinsic value and will short-change existing shareholders," adding that from the perspective of maximizing shareholder value, this is a "terrible time" to sell the company.

The investor also said the offer "severely undervalues" the company and "ensures that the buyers — rather than existing shareholders — will reap the benefits of the value enhancement the improved business will generate."